How supermarkets are changing their branding to make you think they’re cheaper 
South African communities vs Shell: high court victories show that cultural beliefs and practices count in climate cases 
ECB Calls for Monitoring and Possible Regulation of AI in Finance 
Cancer drug pollution is a growing global concern 
Skepta Says Puma Is 'Much Better Deal' Than Nike, Reveals New Sneaker Collaboration 
Tesla Cybertruck Trails Ford F-150 Lightning in Sales as Q1 Figures Disappoint Wall Street 
Nike vs. Adidas: Anthony Edwards’ and Wembanyama’s Sneakers Soar in Popularity 
Brands Like Burger King and Coke Use Scholarships to Capture Gen Z's Attention 
Newsrooms are experimenting with generative AI, warts and all 
Coca-Cola Launches Lens Platform to Offer Key Data for Retail and Foodservice 
Tesla Scrambles to Soothe European Backlash Over Fleet Price Cuts, Maintenance Costs 
McDonald's Faces Backlash Over $5 Meal Deal: Customers Call It 'Skimpy' 
Shein's Potential London IPO Could Revitalize LSE Amid Geopolitical Tensions 
Semaglutide's Benefits Beyond Weight Loss: New Insights from the SELECT Trial 
Skechers Sales Surge as Growth Lags for Nike and Adidas; Nike Eyes 2024 Olympics 
NEW YORK, Feb. 09, 2017 -- TG Therapeutics, Inc. (Nasdaq:TGTX) today announced that Michael S. Weiss, the Company’s Executive Chairman and Chief Executive Officer, will present at the 2017 BIO CEO & Investor Conference, being held at the Waldorf Astoria Hotel in New York City. The presentation is scheduled to take place on Monday, February 13, 2017 at 9:00am ET. A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company’s website at www.tgtherapeutics.com.
ABOUT TG THERAPEUTICS, INC.
TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Currently, the company is developing two therapies targeting hematological malignancies and autoimmune diseases. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. TG Therapeutics is also developing TGR-1202, an orally available PI3K delta inhibitor. The delta isoform of PI3K is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of B‐lymphocytes. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies, with TG-1101 recently entering clinical development for autoimmune disorders. The Company also has pre-clinical programs to develop IRAK4 inhibitors, BET inhibitors, and anti-PD-L1 and anti-GITR antibodies. TG Therapeutics is headquartered in New York City.
TGTX - G
CONTACT: Jenna Bosco Vice President- Investor Relations TG Therapeutics, Inc. Telephone: 212.554.4351 Email: [email protected]
